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Abstract 
Dysregulated lipid metabolism induces an inflammatory and immune response leading to 
atherosclerosis. Conversely, inflammation may alter lipid metabolism. Recent treatment 
strategies in secondary prevention of atherosclerosis support beneficial effects of both 
anti-inflammatory and lipid-lowering therapies beyond current targets. There is a 
controversy about the possibility that anti-inflammatory effects of lipid-lowering therapy 
may be either independent or not of a decrease in low-density lipoprotein cholesterol. In 
this Position Paper, we critically interpret and integrate the results obtained in both 
experimental and clinical studies on anti-inflammatory actions of lipid-lowering therapy 
and the mechanisms involved. We highlight that: (i) besides decreasing cholesterol 
through different mechanisms, most lipid-lowering therapies share anti-inflammatory and 
immunomodulatory properties, and the anti-inflammatory response to lipid-lowering may 
be relevant to predict the effect of treatment, (ii) using surrogates for both lipid metabolism 
and inflammation as biomarkers or vascular inflammation imaging in future studies may 
contribute to a better understanding of the relative importance of different mechanisms of 
action, and (iii) comparative studies of further lipid lowering, anti-inflammation and a 
combination of both are crucial to identify effects that are specific or shared for each 
treatment strategy. 
 
1. Introduction 
Dyslipidaemia and inflammation are closely interconnected key drivers of 
atherosclerosis.1 Dysregulated lipid metabolism induces an inflammatory and immune 
response in atherosclerosis, whereas the beneficial effects of low-density lipoproteins 
(LDLs) lowering on cardiovascular outcomes are associated with decreased 
inflammation. However, the controversy on anti-inflammatory effects of lipid-lowering 
therapy has created a large confusion around the mechanism by which these drugs exert 
beneficial actions. In particular, whether the improved cardiovascular outcome of statins 
solely reflects a decrease in LDL cholesterol, or whether lipid-independent anti-
inflammatory actions prevail has been a matter of debate for a long time. In this regard, 
there is a discrepancy between the results obtained in experimental and clinical studies. 
Since novel treatment strategies in secondary prevention of atherosclerosis argue for 
beneficial effects of both further lipid-lowering2 and anti-inflammation,3 it is crucial to 
clarify whether further lipid-lowering therapy leads to a sufficient anti-inflammatory 
response, and whether adding specific anti-inflammatory therapy can achieve additional 
risk reduction on top of the most efficient lipid lowering. 
 
The recent introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
represents an opportunity to deepen our understanding on the role of lipids on the immune 
and inflammatory responses in atherosclerosis. Likewise, the beneficial effects of IL-ȕ
blockade3 provided the proof of concept for anti-inflammation as a therapeutic strategy 
in cardiovascular disease. In addition, recent post hoc analyses point to inflammatory 
biomarkers for the prediction of cardiovascular outcomes in patients treated with PCSK9 
inhibitors.4,5 These findings have initiated a debate on whether personalized medicine 
can be anticipated based on either basal levels or changes in lipid levels and inflammatory 
biomarkers in response to lipid-lowering and/or anti-inflammatory treatments. 
Thus, it is important to critically interpret and integrate the results obtained in both clinical 
and experimental studies to conclude on possible mechanisms behind these observations 
and to provide arguments for the design of future studies. This Position Paper will provide 
an overview of anti-inflammatory effects of lipid-lowering drugs, aiming to clarify the 
relation and the relevance of lipid-dependent and lipid-independent anti-inflammatory 
effects observed. In addition, this Position Paper underlines the mechanistic insights that 
translate into the observed outcomes and provides a consensus statement on how to 
identify the anti-inflammatory response to lipid lowering therapy. 
2. Dyslipidaemia and immunity²cause or consequence? 
Increased LDL levels are a well-recognized cause of inflammation in atherosclerosis. 
However, the fact that immune cells may also affect lipid metabolism in atherogenesis is 
less well known and may have been overlooked. 
2.1 Lipid-induced immune responses 
Modified LDL (mLDL) increases the endothelial expression of adhesion molecules, 
chemokines, as well as costimulatory and pro-inflammatory molecules, such as CD40 
and nuclear factor-ț%1)-ț%ZKLFKwill promote the recruitment of inflammatory cells 
into the vascular wall. LDL accelerates monocyte to macrophage differentiation8 and this 
macrophage activation involves innate immune receptors, which are strong inducers of 
inflammation and have an established impact on atherosclerosis.9 For example, certain 
components of mLDL activate pattern recognition receptors, such as toll-like receptors 
(TLRs), triggering proinflammatory signals.10 These TLRs in addition prime the NLRP3 
inflammasome through its activation by cholesterol crystals.11 Also, cholesterol-loaded 
smooth muscle cells acquire pro-inflammatory properties.12 Importantly, LDL also 
accumulates in circulating monocytes eliciting a pro-migratory phenotype, supporting that 
the pro-inflammatory paradigm induced by LDL appears both locally in the vascular wall 
and systemically in the circulation.13 B cells are involved in atherogenesis although their 
role is still not clear, with some data suggesting a protective action and others supporting 
a pro-atherogenic function, probably depending on the specific B-cell subset.14 
In addition to innate immune cells, there is also evidence for an effect of lipids on adaptive 
immune responses. For example, stimulation of human CD4+ T cells with 
lysophosphatidylcholine enhances the expression of interferon-ȖDQG&'/DPROHFXOH
that binds to its receptor CD40 triggering the release of multiple inflammatory 
mediators.15 Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis by 
releasing chemokine CXCL1 from endothelium to recruit monocytes, and oxidized LDL 
increases metalloproteinase-9 (MMP-9) expression and NF-ț% DFWLYLW\ LQ KXPDQ
macrophages.7 These data provide an essential mechanism by which lipids activate 
genes involved in immune responses in atherosclerosis. 
High-density lipoprotein (HDL) has been said traditionally to induce atheroprotection. 
Bone marrow and splenic reservoirs of leucocytes accelerate atherosclerosis after 
myocardial infarction by liberating haematopoietic stem cells and progenitor cells.16 
Conversely, HDL suppresses proliferation of these haematopoietic stem cells and 
myelopoiesis with anti-atherogenic effects mediated by ABCA1 (ATP-binding cassette 
transporter-1) and ABCG1 (ATP-binding cassette sub-family G member-1).17 
Importantly, the benefits of HDL can be lost in hypercholesterolaemia18 and also in other 
conditions, such as chronic kidney disease.19 In addition, despite these reported benefits, 
recent data suggest that extreme high HDL may be associated with high mortality in the 
general population.20 Thus, more studies are needed to ascertain the mechanisms 
underlying these findings. 
Dietary lipid modifications can also influence the immune response. In humans, NF-ț%
activity in circulating leucocytes is enhanced after a fat-enriched meal.21 Accordingly, 
low-fat diet reduces high-sensitivity C-reactive protein (CRP) levels,22 and 
Mediterranean diet decreases the expression of pro-inflammatory and prothrombotic 
genes.23 Also, monocyte cholesterol content increases following oral fat ingestion, 
showing a pro-inflammatory phenotype, comprising increased CD11c/CD18 
expression.24 Then, besides LDL, triglyceride-rich particles, including cholesterol 
remnant particles, may equally contribute to pro-inflammatory changes. 
In summary, lipid metabolism has profound effects on both innate and adaptive immunity 
via multiple mechanisms. 
2.2 Inflammation modifies lipid metabolism 
Both innate and adaptive immune processes regulate lipid metabolism (Figure 1). Several 
innate immune cytokines accelerate hepatic steatosis by influencing fatty acid 
biosynthesis and oxidation.25 Thus, subacute inflammation enhances the expression of 
sterol regulatory element-binding proteins (SREBPs),26 the master regulators of lipid 
biosynthesis. Innate immune cytokines can also influence lipoprotein lipase in adipose 
and muscle tissue27,28 leading to dysfunctional triglyceride clearance and increased 
plasma very-low density lipoprotein (VLDL) levels. Also, TLR activation inhibits 
cholesterol efflux by suppressing LXR (liver X receptor)-mediated induction of ABCA1 
expression, thereby inhibiting reverse cholesterol transport.29 
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Mechanisms through which inflammation may promote dyslipidaemia. Inflammation 
enhances SRBEPs (sterol regulatory element binding proteins). The interaction of co-
stimulatory molecule LIGHT (lymphotoxin-related inducible ligand) with LTßR 
(lymphotoxin ß receptor), and the impairment of Tregs (T regulatory cells) responses 
decrease the expression of several lipases. TLR (Toll-like receptor) activation reduces 
reverse cholesterol transport through a suppression of ABCA1 expression. Finally, 
dysregulation of intestinal microbiome increases lipid levels via an enhanced permeability 
of the intestinal barrier. 
The adaptive immune system can also influence lipoprotein metabolism. The interaction 
between the costimulatory molecule LIGHT (lymphotoxin-related inducible ligand) on T 
FHOOV DQG O\PSKRWR[LQ ȕ UHFHSWRU /7ȕ5 RQ KHSDWRF\WHV GHFUHDVHV KHSDWLF OLSDVH
activity, impairs VLDL and LDL turnover, increasing plasma lipids.30 Similarly, enhanced 
hepatic inflammation due to impaired T regulatory cell (Treg) responses alters the 
expression of several lipid metabolism-related genes including sortilin-1 (Sort-1), 
lipoprotein lipase, hepatic lipase, and phospholipid transfer protein resulting in 
hypercholesterolaemia.31 In this regard, low Treg numbers or decreased Treg/effector T 
cell ratios are associated with cardiovascular disease.32 In adddition to these effects, 
during acute infections and sepsis, HDL gets dysfunctional and promotes 
inflammation.33,34 
Interestingly, other chronic inflammatory diseases show increased triglycerides, small 
dense LDL, and lipoprotein (a) (Lp(a)), and decreased HDL levels.27 In addition, a 
dysregulated intestinal microbiome with enhanced permeability of the intestinal barrier 
affects metabolic diseases35 and atherosclerosis,36 being associated with increased 
LDL, VLDL, and total cholesterol, and with more extensive atherosclerosis in the apoE-/- 
mouse model.37 Also, intestinal inflammation may be associated to a decrease in trans-
intestinal cholesterol efflux, increasing blood lipid levels.38 
Altogether, these data indicate that the inflammatory and immune response affects lipid 
metabolism, establishing a vicious circle that promotes atherogenesis. 
2.3 Effects of anti-inflammatory therapies on lipids and cardiovascular risk 
Anti-inflammatory therapies show a varied range of effects on lipids and cardiovascular 
risk. First, non-steroidal anti-inflammatory drugs are associated with an increased risk of 
cardiovascular events.39,40 Glucocorticoids, the other widely used anti-inflammatory 
drugs, have been associated with increases in HDL/total cholesterol ratio,41 but also with 
enhanced VLDL and triglyceride production.42 Nevertheless, they show no effect on 
cardiovascular risk in secondary prevention.43 
Anti-TNF therapy may lead to an increase in HDL without LDL changes,44 or to a modest 
rise in total cholesterol,45 although these effects may depend on the drug used. The 
impact of these changes on cardiovascular risk may be more complex, as anti-TNF 
therapies have been linked with a decreased number of cardiovascular events in 
rheumatoid arthritis patients. However, these results come mainly from observational 
studies,46 and large randomized clinical trials are needed to confirm this effect. 
Another biologic therapy, tocilizumab, an IL-6 receptor blocker, increases total 
cholesterol, LDL, and triglyceride levels, but shifts HDL particles towards an anti-
inflammatory composition.47 In contrast, the Canakinumab Antiinflammatory Thrombosis 
Outcome Study (CANTOS) demonstrated that IL-ȕEORFNDGHZLWKFDQDNLQXPDE(?PJ
every three months reduces the incidence of nonfatal myocardial infarction, nonfatal 
stroke, or cardiovascular death [hazard ratio (HR) 0.85, 95% confidence interval (CI) 
0.74±0.98; P(? (?@ ZLWKRXW DIIHFWLQJ OLSLG OHYHOV H[FHSW IRU DPLOG LQFUHDVH LQ
triglycerides.3 
Methotrexate has been associated with both, unfavourable and beneficial lipid changes 
and an improved macrophage cholesterol handing.48,49 Regarding its effect on 
cardiovascular risk, the Cardiovascular Inflammation Reduction trial (CIRT) testing low 
dose methotrexate against placebo in secondary prevention has been discontinued 
earlier than scheduled (https://www.forbes.com/sites/larryhusten/2018/05/21/nih-halts-
large-cardiovascular-inflammation-reduction-cirt-trial/#4cc3a12 c5b5f) but the results are 
still pending. 
Finally, in a study including 532 patients with stable coronary artery disease, colchicine 
reduced the incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or 
noncardioembolic ischaemic stroke (HR 0.33, 95% CI 0.18±0.59; P(?(? 7KLV
effect is now being tested in two large clinical trials: the LoDoCo2 
(http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=LoDoCo2&isBasic=True) and the 
COLCOT studies (https://clinicaltrials.gov/ct2/show/NCT02551094). 
Thus, studies of anti-inflammatory treatments have generated contradictory results in 
terms of their effects on lipids. Although the heterogeneous patient populations and 
different inflammatory targets studied preclude a definite conclusion, monitoring of lipid 
levels appears to be crucial in studies of anti-inflammation in cardiovascular prevention. 
3. Statins and immunity: current status 
3.1 Experimental data 
In in vitro studies statins inhibit the expression of adhesion molecules in both endothelial 
cells and monocytes,51 as well as LDL-induced endothelial nitric oxide synthase down-
regulation.52 In addition, statins reduce NF-ț% DFWLYDWLRQ DQG FKHPRNLQH DQG 003
expression53,54 and promote the expression of anti-inflammatory and cytoprotective 
molecules in endothelium.55 
Statins also modulate the adaptive immune response by inhibiting the expression of major 
histocompatibility class II required for antigen presentation to effector T cells56 and divert 
T cell differentiation to Tregs, that supress pro-inflammatory responses of other immune 
cells and counteract pro-inflammatory IL-17-producing T cell differentiation (Th17).57 
Statins also up-regulate the expression of Kruppel-like factor 2 (KLF2) in mouse and 
human T cells, diminishing interferon-ȖH[SUHVVLRQDV./)FRQWUROVWKHH[SUHVVLRQRI
molecules essential for naive T cell recirculation and maintenance of T cell quiescence. 
3.2 Evidence in humans 
Further proof of concept for anti-inflammatory effects of statins was provided by studies 
of patients scheduled to elective carotid endarterectomy randomized to either statins or 
no lipid-lowering therapy.59 Plaques from patients under statins exhibited reduced NF-
ț% DFWLYLW\ GHFUHDVHG PDFURSKDJH DQG 7 FHOO LQILOWUDWHV DQG OHVV H[SUHVVLRQ RI
proinflammatory mediators.59 Moreover, statins diminish plasma levels of CRP, 
cytokines, and adhesion molecules60,61 and decrease microparticle shedding from 
inflammatory cells.62 
The anti-inflammatory effects of statins have been postulated to contribute to their clinical 
benefits. Accordingly, statins are especially effective when associated to a diminution in 
CRP levels.63 Furthermore, it has been suggested that statins may be more effective in 
patients with high CRP levels.61,64,65 However, this could be due to the higher 
cardiovascular risk of these patients and discordant data also exist.66 Also, mendelian 
randomization analyses suggest that CRP concentration itself is unlikely to be a causal 
factor of coronary artery disease.67 Thus, at present, CRP determination is not advised 
as its contribution to the existing methods of cardiovascular risk assessment seems to be 
small.68 
The immunomodulatory effects of statins are also supported by data on clinical outcomes. 
Statins decrease the cytotoxicity of natural killer cells, and the incidence of coronary 
vasculopathy and rejection with dynamic impairment after a cardiac transplant.69 Other 
studies have also found a lower incidence of coronary artery disease and intimal 
thickening without reducing the incidence of cardiac rejection.70 Conversely, in patients 
with kidney transplantation, there are no consistent data confirming this 
immunomodulatory effect.71,72 
In addition, imaging vascular inflammation by techniques such as PET (positron emission 
tomography) using FDG (18F-fluorodeoxyglucose) has evidenced that statins achieve a 
decrease of vascular inflammation consistent with the reduction of the cardiovascular risk 
observed in clinical trials.73 This is relevant, as a lack of reduction in arterial FDG uptake 
by anti-inflammatory therapies has been associated with an absence of clinical benefit.74 
In conclusion, both experimental and clinical data support that statins have anti-
inflammatory and immunomodulatory properties. Nevertheless, a legitimate question is 
whether these actions could be, at least in part, independent of their lipid-lowering effects. 
3.3 Lipid-independent anti-inflammatory and immunomodulatory effects of statins 
Some intermediate compounds of the mevalonate pathway that is blocked by statins to 
decrease cholesterol synthesis, are implicated in post-translational modifications of key 
proteins75 involved in important cell functions. Among them, small G proteins75 play a 
role in cell signal transduction, and their blockade in atherosclerotic cells might interfere 
with atherogenesis irrespective of the inhibition of cholesterol synthesis.75 In this regard, 
statins have anti-inflammatory effects in vitro in the absence of changes in lipid 
concentrations.53 In animal models, they have stronger anti-inflammatory effects than 
diet modification in spite of less decrease in cholesterol levels.76 Moreover, they reduce 
inflammation in models of inflammatory disorders likely unrelated to lipids.77±79 
In humans, however, data are less clear. In the Atorvastatin in Rheumatoid Arthritis 
(TARA) trial, atorvastatin modestly decreased iQIODPPDWLRQ ZLWK D GLPLQXWLRQ RI í
&,íWRíLQWKHGLVHDVHDFWLYLW\VFRUHZKHQFRPSDUHGZLWK&,
í0.23 to 0.28) in the placebo group (P(? (? DQ HIIHFW WKDW FRXOG EH OLSLG-
independent. However, in another study ezetimibe, that decrease LDL through a different 
PHFKDQLVPDFKLHYHGDOVRDPLOGEXWVLJQLILFDQWUHGXFWLRQLQWKHDFWLYLW\VFRUHRIí
1.01 (P(? (? WKDW ZDV VLPLODU WR WKDW REWDLQHG E\ VLPYDVWDWLQ í  
P(? (? $FFRUGLQJO\ 3&6.-antibodies reduce the pro-inflammatory changes in 
circulating monocytes, coinciding with a marked decrease in monocyte-cholesterol 
content.13 Then, LDL lowering may be the predominant factor explaining anti-
inflammatory effects in humans. In fact, risk reduction of major vascular events is similar 
in statin and non-statin therapies [0.77 (95% CI 0.71±0.84) and 0.77 (95% CI 0.75±0.79) 
SHU(?PJG//'/GHFUHDVHUHVSHFWLYHO\P(?(?IRUERWK@ 
Thus, although basic research suggests that statins have lipid-independent anti-
inflammatory effects, this seems difficult to confirm in humans. This discrepancy may 
reflect the biodistribution of statins. In this regard, a nano-particulate formulation statin 
packaged in HDL particles exerts potent anti-inflammatory effects in plaques, as it 
delivers the statin into the plaque macrophages directly.83,84 In contrast, oral statins in 
equal doses hardly affect plaque inflammation, illustrating that the first-pass clearance of 
statins by the liver precludes a strong anti-inflammatory effect in vivo. 
4. Non-statin LDL-lowering drugs and inflammation 
The relationship between lipids and inflammation is supported by the observation that 
non-statin lipid-lowering drugs also have anti-inflammatory effects. In this regard, 
ezetimibe also diminishes plaque inflammation in models of atherosclerosis.85 
Accordingly, in patients at high cardiovascular risk, ezetimibe reduces plasma levels of 
inflammatory markers.86 Similarly to data reported with statins, achievement of both CRP 
and LDL prespecified targets in patients receiving ezetimibe and statin combination 
therapy is associated with better outcomes than reaching only LDL target levels.87 Then, 
non-statin LDL-lowering drugs also show anti-inflammatory properties despite working 
through different mechanisms, suggesting that lipid reduction plays a key role in these 
effects. In this regard, recent data show that lipid reduction is associated to a modulation 
of the inflammatory response irrespective of the lipid-lowering therapy used.88 
Specifically, the reduction obtained in CRP levels with statins and with their combination 
with ezetimibe is proportional to the reduction observed in LDL levels.88 
5. PCSK9 inhibition 
5.1 PCSK9: an endogenous inhibitor of the LDL receptor 
PCSK9 mediates intracellular degradation of the hepatic LDL receptor (LDLR).89 Once 
secreted by the hepatocyte, PCSK9 binds to the extra-cellular EGF-A domain of the 
LDLR, leading to the internalization of the LDLR-PCSK9 complex through clathrin-coated 
pits.90 In addition, PCSK9 could also enhance LDLR degradation by an intra-cellular 
pathway not requiring PCSK9 secretion.91 In this regard, the S127R PCSK9 gain-of-
function variant leads to autosomal dominant hypercholesterolaemia without PCSK9 
secretion.92 
PCSK9 monoclonal antibodies block the extracellular PCSK9 pathway reducing LDL, 
triglyceride, cholesterol and Lp(a) plasma levels, and increasing HDL and ApoA1 levels.2 
These data translate into a decrease in the incidence of cardiovascular events in 
secondary prevention2 (http://www.acc.org/latest-in-cardiology/clinical-
trials/2018/03/09/08/02/odyssey-outcomes). 
5.2 PCSK9 and inflammation 
The fact that the recently developed PCSK9 inhibitors do not reduce plasma CRP13 has 
lead to the idea that they may not have anti-inflammatory effects (Figure 2). However, 
many data indicate that these drugs share anti-inflammatory actions with other lipid-
lowering drugs. Even more, PCSK9 itself could have pro-inflammatory effects. 
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Role of PCSK9 in sepsis and inflammation. Hepatic PCSK9 expression is induced by 
71)ĮKHSDWRF\WHQXFOHDUIDFWRU-Į+1)-ĮDQGOLSRSRO\VDFFKDULGH/362QFHLQWKH
plasma, PCSK9 binds to the LDL receptor facilitating LDL degradation in lysosomes, thus 
decreasing clearance of LDL-bound LPS. Extracellular PCSK9 also enhances the 
expression of pro-inflammatory markers, decreases macrophages in atheroma, and the 
expression of LDLR and ABCA1 in these cells. It also forms a complex with Lp(a). The 
intracellular function of PCSK9 in inflammation remains unknown. GNB, gram-negative 
bacteria; mab, monoclonal antibody. 
The transcriptional regulation of PCSK9 suggests that it may have a role in inflammation. 
PCSK9 expression is induced by hepatocyte nuclear factor-Į+1)-ĮZKLFKUHJXODWHV
the expression of acute phase pro-inflammatory proteins.93 Also, lipopolysaccharide 
induces early hepatic and renal PCSK9 mRNA expression in mice,94 as well as in 
HQGRWKHOLDO DQG YDVFXODU VPRRWK PXVFOH FHOOV )LQDOO\ 71)Į LQFUHDVHV 3&6.
expression in vitro in cultured macrophages.96 In humans, plasma PCSK9 
concentrations increase in sepsis,97 trauma,98 and in acute coronary syndromes. 
Furthermore, they are positively associated with white blood cell count, fibrinogen,99 and 
CRP100 in coronary patients. To date, there are no data reporting the effects of anti-
inflammatory molecules on PCSK9 levels. 
While PCSK9 expression in macrophages is debatable, data suggest that it modulates 
LDLR expression in these cells, either through a paracrine101 and/or autocrine 
mechanism102 and also stimulates the expression of scavenger receptors (principally 
LOX-1) and ox-LDL uptake in these cells.96 Furthermore, PCSK9 silencing reduces 
oxLDL-induced cytokine expression in THP-1 derived macrophages through NF-ț%
inhibition103 and decreases TLR4 expression and NF-ț% activation in oxLDL-treated 
macrophages.104 Conversely, overexpression of human PCSK9 in lipopolysaccharide-
stimulated macrophages promotes the expression of pro-inflammatory markers, while 
inhibiting anti-inflammatory molecules.102 Similarly, PCSK9 overexSUHVVLRQ LQ 71)Į-
primed macrophages enhances the expression of scavenger receptors.96 Bone marrow 
transplantation from mice expressing human PCSK9 (hPCSK9tg) in apoE knockout mice 
generated a chimeric model expressing hPCSK9 only in macrophages.102 Interestingly, 
despite not modifying lipid levels, transplanted animals showed a LDLR-dependent 
increased number of Ly6Chi inflammatory monocytes within atherosclerotic lesions and 
spleens, and a reduction of LDLR expression in macrophages.102 Furthermore, PCSK9 
decreases ABCA1 expression, thereby reducing cholesterol efflux in macrophages at 
least partly in a LDLR-dependent manner.105 In addition, human recombinant PCSK9 
induces the expression of monocyte chemoattractant protein-1, IL6 and other pro-
inflammatory cytokines in both THP-1 derived and human primary macrophages.106 
Altogether, these data suggest that PCSK9 may locally regulate atherosclerotic plaque 
inflammation. Accordingly, the ATHEROREMO-IVUS study found that circulating PCSK9 
levels were positively associated with the extent of necrotic core in atheroma, 
independently of LDL levels in patients with acute coronary syndrome.107 Moreover, 
PCSK9 inhibition with alirocumab in APOE*3 Leiden.CETP mice, decreases macrophage 
and necrotic core content and increases vascular smooth muscle cells and collagen 
content.108 
Regarding the effects of PCSK9 inhibition on inflammation in humans, it reduces Lp(a) 
levels,109 a molecule that circulates bound to PCSK9 in plasma,110 and promotes 
inflammation and oxidative stress and coagulation. Also, PCSK9-antibody therapy 
markedly reduces monocyte inflammatory phenotype in patients with familial 
hypercholesterolaemia, without any change in plasma hsCRP concentration.13 A similar 
lack of effect on hsCRP levels has been described in large cardiovascular outcomes 
trials.4 This emphasizes the potential for anti-inflammatory effects without reduction in 
the liver-derived acute phase reactant hsCRP.111 
5.3 PCSK9 and septic shock 
Beyond its lipid-lowering action, as lipopolysaccharide circulates bound to LDL, up-
regulation of hepatic LDLR by PCSK9 inhibition has been suggested to result in increased 
lipopolysaccharide clearance (Figure 2), a decreased inflammatory response, and 
improved survival following sepsis in mice112,113 although, in a recent study, PCSK9 
inhibition failed to reduce LPS-induced mortality in mice.114 Importantly, humans with 
PCSK9 loss-of-function variants also exhibit improved clinical outcomes during septic 
shock.115 Finally, enhanced plasma PCSK9 levels during sepsis are associated with 
multiple organ failure.97 Based on these results, clinical trials are planned to assess the 
effect of PCSK9 inhibition outcomes during sepsis. 
5.4 Vascular actions of PCSK9 
PCSK9 is expressed in many other tissues than the liver, including atherosclerotic 
plaques,101,116 and vascular areas of low shear stress, that are prone to develop 
atherosclerosis.95 PCSK9 expression is found mainly in vascular smooth muscle 
cells,101 and to a lesser extent in endothelial cells.95 PCSK9 deficiency reduces 
neointimal formation following injury of the carotid artery in mice beyond cholesterol 
lowering by decreasing vascular smooth muscle cell migration and proliferation rate.117 
Recent epidemiological studies have demonstrated that plasma PCSK9 levels are 
associated with carotid atherosclerosis118 independently of LDL. However, other data 
challenge the idea of a lipid-independent effects of PCSK9 inhibitors. For instance, 
plasma PCSK9 levels have not proven consistently to predict cardiovascular 
events.100,119,120 Moreover, in the GLAGOV trial a linear relationship was found 
between the regression of atheroma and the decrease of LDL achieved with 
evolocumab.121 Finally, the risk reduction observed with PCSK9 inhibitors in clinical 
trials, seems to be fully explained by the decrease of LDL achieved, suggesting that the 
anti-atherosclerotic benefit of this therapy is directly related to LDL reduction.122 
However, inflammation may affect the response to PCSK9 inhibition as suggested by very 
recent post hoc analyses of PCSK9 trials.4 First, patients with high CRP at baseline obtain 
greater benefit with PCSK9 inhibitors.4 Second, patients with persistent high CRP levels 
after initiating treatment with statins and PSCK9 inhibitors have a worse prognosis.5 
Although the risk reductions obtained in these trials seem to be fully explained by the 
decrease in LDL cholesterol, a more marked beneficial response to PCSK9 inhibition may 
hence be predicted in patients with high inflammatory levels. 
Consensus statements 
 
1 Lipid reduction is associated with modulation of the inflammatory and immune 
responses irrespective of the lipid-lowering therapy used. Despite decreasing 
cholesterol through different mechanisms, most lipid-lowering therapies, including 
dietary interventions, share anti-inflammatory, and immunomodulatory properties. 
This observation provides strong evidence that lipid lowering per se causes 
alterations in inflammation and immunity. Some lipid-lowering drugs also directly 
target lipid-independent pathways to reduce inflammation in experimental and 
exploratory studies. However, a contribution of these effects to cardiovascular 
outcomes is unclear, and further studies are required to address this question. 
However, regardless of the mechanism involved, an anti-inflammatory response 
to lipid-lowering may be of clinical importance to predict the effect of treatment. 
2 Using surrogates for both lipid metabolism and inflammation as biomarkers in future 
studies may contribute to a better understanding of the relative importance of 
different mechanisms of action. Given the strong association between 
inflammation, lipids and atherosclerosis, assessment of the inflammatory response 
to lipid-lowering interventions could be helpful to establish optimal dose and type 
of lipid-lowering therapy in cardiovascular prevention. There is still an unmet need 
for new biomarkers and further validation of existing biomarkers that more closely 
reflect the inflammatory activity in atherosclerosis before such approach can be 
implemented.123 In this regard, at present, CRP determination is not adviced as 
it adds small value to the existing methods of cardiovascular risk assessment.68 
Also, imaging vascular inflammation by techniques such as PET show promise to 
assess the anti-inflammatory effect of lipid-lowering therapies. Furthermore, we 
raise the notion of lipid monitoring in studies of anti-inflammatory therapies. 
3 Comparative studies of further lipid lowering, anti-inflammation and a combination of 
both will be crucial to identify effects that are specific or shared for each treatment 
strategy. Current experimental and clinical research evidence discussed in the 
present Position Paper can be used to design a head-to-head comparison of the 
potential beneficial effects of additional anti-inflammation or lipid lowering 
therapies or the combination of both regimens to current medical standards in 
secondary prevention. In this context, personalized medicine could be anticipated 
based on predictive factors for a beneficial response to lipid lowering and/or 
inflammatory levels in secondary prevention. 
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